Title: Proton Therapy for Children: China Clinical Report | ChildMedCare Canonical page: https://childmedcare.com/resources/miniaturized-proton-therapy-clinical-use-children/ Language: English [Home](https://childmedcare.com/)/[Story & News](https://childmedcare.com/resources/)/News News # Miniaturized proton therapy in clinical use, pediatric tumors listed ChildMedCare editorial teamPublished November 1, 20265 min read Reported for October 27, 2026 · Archive-based summary A miniaturized proton system is in clinical use in China, with pediatric tumors named in the report. What international families need to verify. AT A GLANCEA Chinese hospital has reported that a miniaturized proton therapy system is in clinical use, with pediatric tumors among the disease types already treated and more than 120 oncology patients treated since June 2026. For an international family, the usable step is not the headline but the specific question: which pediatric cases this center has handled, whether international intake is open, and what the current scheduling window looks like. Nothing in the report establishes eligibility, price or outcome for an individual child. In this article[What the October report says](#article-section-1)[Which two details are actually usable](#article-section-2)[Reported versus still to confirm](#article-section-3)[Institutional news is not an offer to your child](#article-section-4)[A dated payment item worth putting in the plan](#article-section-5)[Questions to put to a proton center before you commit to travel](#article-section-6)[Planning checklist](#article-checklist)[Sources](#article-sources) ## What the October report says On October 27, 2026, Science and Technology Daily reported that China-Japan Friendship Hospital has put a miniaturized proton therapy system into clinical use, and that pediatric tumors are among the disease types already treated there. The item came from a proton therapy academic symposium and the founding ceremony of a miniaturized proton working alliance. According to the report, the hospital carried out its first lung cancer proton treatment in June 2026 and has since completed therapy for more than 120 oncology patients, across lung cancer, prostate cancer, pediatric tumors and other categories. Zhuang Hongqing, deputy director of the hospital’s radiation oncology department, is quoted saying that the dose-distribution characteristics of proton therapy allow better protection of surrounding normal tissue and organs. ## Which two details are actually usable For a family whose child has a solid tumor and a radiotherapy decision on the table, two specifics matter. First, the system is described as in clinical use rather than planned or under construction, so there is an operational pathway to ask about. Second, pediatric tumors appear in the list of disease types the hospital reports having treated, which moves the question from theoretical to concrete. The report does not go further than that. It does not state how many of the more than 120 patients were children, which tumor types or age groups were involved, which protocols were used, how long the waiting time is, or whether patients from outside mainland China are accepted. Those gaps are questions for the treating center, not spaces to fill with assumptions. ## Reported versus still to confirm Reported versus still to confirm - Question for the center: What the report states: What remains unconfirmed - Pediatric proton treatment: Pediatric tumors listed among treated disease types: Number of child patients, tumor types and ages - Case volume: More than 120 oncology patients since June 2026: How many were children, and at which site - Eligibility for one child: Not addressed: A clinical decision after imaging, pathology and prior treatment records are reviewed - International patient intake: Not addressed: Whether intake is open and on what terms - Scheduling: Not addressed: Current waiting time from records submission to treatment start - Cost and payment: Not addressed: A dated written estimate and the insurer’s written reply ## Institutional news is not an offer to your child The working alliance described in the report is an organizational structure, and the treatment figures belong to an institution, not to any individual patient. None of it establishes that a particular child is a candidate, that an appointment can be obtained, that a slot will open within a given window, or that a price or a result can be promised. Whether proton radiotherapy is appropriate for a specific child is a judgment for the treating radiation oncology team after an in-person or records-based clinical review; it is not something this article, a coordinator or a news report can decide. ChildMedCare is an independent editorial resource for international families. It is not a hospital, does not speak for China-Japan Friendship Hospital or Shanghai Children’s Medical Center, and cannot register a patient or confirm availability, schedules or costs. Any statement about those items must come from the hospital in writing. ## A dated payment item worth putting in the plan Where a child’s plan includes specialty medicines — pediatric oncology and rare-disease protocols are where cost usually bites — the national payer calendar is concrete. The National Healthcare Security Administration announced on October 20, 2026 that on-site negotiation, bidding and price consultation for the 2026 basic medical insurance drug catalog and the commercial insurance innovative drug catalog had been completed and confirmed in September, with companies able to download and sign agreements from that date. The new catalogs are expected to be published in November 2026 and to take effect on January 1, 2027. A total of 124 out-of-catalog drugs entered the adjustment, with rare-disease and pediatric medicines named as priority areas, and the dual-catalog mechanism allows items on the commercial insurance innovative drug list to be submitted for the basic catalog. This is a catalog process, not a coverage decision for any one medicine or any one family, and the reports do not address reimbursement for proton radiotherapy itself. Whether a plan pays is answered in writing by the insurer, not by a directory announcement. ## Questions to put to a proton center before you commit to travel - Has this center treated children with my child’s tumor type and age, and how many cases? - Is international patient intake open, and who receives the records for review? - What is the current waiting time from records review to simulation and first treatment? - What is the quoted cost for the full treatment course, in writing, and what is excluded? - Which documents, translations or certifications are needed before clinical review? - How is the schedule handled if coverage confirmation or visa timing changes? ## Planning checklist - Ask the center: pediatric tumor types treated and case numbers - Confirm international intake and current waiting time in writing - Request a dated treatment-course cost estimate with exclusions - Obtain the insurer’s written coverage position before booking - Prepare imaging, pathology and prior radiotherapy records - Note the November 2026 catalog publication and January 2027 date ## Sources & further reading - [中日友好医院小型化质子治疗系统应用于临床，已完成120余例并覆盖儿童肿瘤 ↗](https://www.stdaily.com/web/gdxw/2026-10/27/content_603631.html)Clinical use of the miniaturized proton system, the symposium and alliance founding, the first June 2026 lung cancer treatment, the more-than-120-patient figure, pediatric tumors among treated disease types, and the quoted dose-distribution statement. - [国家医保局：2026年基本医保药品目录及商保创新药目录现场谈判、竞价、价格协商已完成并现场确认，企业即日起下载签署协议 ↗](https://www.nhsa.gov.cn/art/2026-10-20/art_14_23170.html)Completion and on-site confirmation of the September 2026 negotiations, the October 20, 2026 agreement-signing notice, the expected November 2026 publication and January 1, 2027 effective date, the 124-drug adjustment scope with rare-disease and pediatric medicines as priorities, and the dual-catalog mechanism. Sources checked November 1, 2026. Planning checklists are ChildMedCare editorial guidance; they are not hospital admission requirements. VISIT COORDINATION ### Planning a hospital visit? Ask about the inquiry process, accommodation, local transfers and hospital accompaniment. [International patient guide](https://childmedcare.com/international-patients/) ### Related services [Blood & cancer care](https://childmedcare.com/care/pediatric-hematology-oncology/)[Hospital information](https://childmedcare.com/resources/childhood-leukemia-review-records-and-questions/)[Hospital information](https://childmedcare.com/resources/medical-records-for-a-pediatric-hospital-review/)[Hospital information](https://childmedcare.com/resources/pediatric-care-cost-estimate-checklist/) ## Related reading. [All articles](https://childmedcare.com/resources/) [ArticleOctober 25, 2026 ### Preparing medical records for a pediatric hospital review in Shanghai Start with a brief inquiry. Ask the receiving hospital which records, formats and translations it needs before uploading files or booking travel.3 min read](https://childmedcare.com/resources/medical-records-for-a-pediatric-hospital-review/)[ArticleOctober 25, 2026 ### How to compare a pediatric care cost estimate for a visit to China Compare the scope of an estimate before comparing its total. Keep hospital charges, coordination services and travel costs in separate budget lines.3 min read](https://childmedcare.com/resources/pediatric-care-cost-estimate-checklist/)[ArticleOctober 25, 2026 ### Childhood leukemia: organizing a specialist review and the questions to ask A leukemia review depends on the exact diagnosis and existing test results. Ask the receiving clinical team what material it needs and keep the current treating team involved.3 min read](https://childmedcare.com/resources/childhood-leukemia-review-records-and-questions/) ## Contact and service scope Email: [contact@childmedcare.com](mailto:contact@childmedcare.com). To contact the coordination team, visit [ChildMedCare](https://childmedcare.com/resources/miniaturized-proton-therapy-clinical-use-children/) and choose “Talk to our team” or “Start a private inquiry”. Inquiries are private and are not published. Do not include a child’s identifying details or medical records. ChildMedCare is an independent coordination service, not the hospital’s official website and not a provider of diagnosis or treatment. Clinical services, appointments, pricing and language arrangements require hospital confirmation.